Pharmaceutical Biotechnology 2E - Drug Discovery And Clinical Applications

The first edition focused on artificial molecules as potential drugs, and not so much on production strategies and the underlying molecular concepts. This second edition reflects the important role molecular biology techniques and genetics are beginning to play in pharmaceuticals. Researchers cover concepts and methods for recombinant drug production, bringing the drug into action--from downstreaming to approval, vaccines, and recent applications. Among specific topics are prokaryotic cells in biotech production, the production of biopharmaceuticals in transgenic animals, drug approval in the European Union and the US, new nanobiotechnology strategies for developing vectors for cancer vaccines, the metabolic engineering of medicinal plants and microrganisms to produce natural products, and xenotransplantation. Annotation c2012 Book News, Inc., Portland, OR (booknews.com)

Oliver Kayser: Oliver Kayser received his PhD at the Free University Berlin in 1997 following his fellowship at the University of Gainesville, Florida, whereupon he entered the pharmaceutical biotechnology industry. He is currently a lecturer at the Department of Pharmaceutics, Biopharmacy and Biotechnology at the FU Berlin, working on new biotech drugs from natural sources and on the development of drug delivery carriers based on nanosuspension and solid lipid nanoparticle enterprise technologies.


Prof. Dr. Heribert Warzecha
Studied Pharmazie at the Johannes Gutenberg-Universit?t, Mainz. After completing his Ph.D. in 1998, he worked first as a postdoctoral fellow at Cornell, USA, and become associate Professor in w?rzburg in 2001. Since 2007 he is full Professor at the technical university of Darmstadt and became dean of the Institute of plant science in 2009.